IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v14y2017i1p68-d87618.html
   My bibliography  Save this article

New Immunotherapy Strategies in Breast Cancer

Author

Listed:
  • Lin-Yu Yu

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Jie Tang

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Cong-Min Zhang

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Wen-Jing Zeng

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Han Yan

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Mu-Peng Li

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

  • Xiao-Ping Chen

    (Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
    Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China)

Abstract

Breast cancer is the most commonly diagnosed cancer among women. Therapeutic treatments for breast cancer generally include surgery, chemotherapy, radiotherapy, endocrinotherapy and molecular targeted therapy. With the development of molecular biology, immunology and pharmacogenomics, immunotherapy becomes a promising new field in breast cancer therapies. In this review, we discussed recent progress in breast cancer immunotherapy, including cancer vaccines, bispecific antibodies, and immune checkpoint inhibitors. Several additional immunotherapy modalities in early stages of development are also highlighted. It is believed that these new immunotherapeutic strategies will ultimately change the current status of breast cancer therapies.

Suggested Citation

  • Lin-Yu Yu & Jie Tang & Cong-Min Zhang & Wen-Jing Zeng & Han Yan & Mu-Peng Li & Xiao-Ping Chen, 2017. "New Immunotherapy Strategies in Breast Cancer," IJERPH, MDPI, vol. 14(1), pages 1-18, January.
    • Handle: RePEc:gam:jijerp:v:14:y:2017:i:1:p:68-:d:87618
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/14/1/68/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/14/1/68/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Roy S. Herbst & Jean-Charles Soria & Marcin Kowanetz & Gregg D. Fine & Omid Hamid & Michael S. Gordon & Jeffery A. Sosman & David F. McDermott & John D. Powderly & Scott N. Gettinger & Holbrook E. K. , 2014. "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients," Nature, Nature, vol. 515(7528), pages 563-567, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jing Liu & Xia Bu & Chen Chu & Xiaoming Dai & John M. Asara & Piotr Sicinski & Gordon J. Freeman & Wenyi Wei, 2023. "PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    2. Kristian Bjørn Hessellund & Ganggang Xu & Yongtao Guan & Rasmus Waagepetersen, 2022. "Second‐order semi‐parametric inference for multivariate log Gaussian Cox processes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 71(1), pages 244-268, January.
    3. Jingjie Yi & Omid Tavana & Huan Li & Donglai Wang & Richard J. Baer & Wei Gu, 2023. "Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    4. Elaine Lai-Han Leung & Run-Ze Li & Xing-Xing Fan & Lily Yan Wang & Yan Wang & Zebo Jiang & Jumin Huang & Hu-Dan Pan & Yue Fan & Hongmei Xu & Feng Wang & Haopeng Rui & Piu Wong & Hermi Sumatoh & Michae, 2023. "Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    5. Weicai Huang & Yuming Jiang & Wenjun Xiong & Zepang Sun & Chuanli Chen & Qingyu Yuan & Kangneng Zhou & Zhen Han & Hao Feng & Hao Chen & Xiaokun Liang & Shitong Yu & Yanfeng Hu & Jiang Yu & Yan Chen & , 2022. "Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    6. Le Qin & Yuanbin Cui & Tingjie Yuan & Dongmei Chen & Ruocong Zhao & Shanglin Li & Zhiwu Jiang & Qiting Wu & Youguo Long & Suna Wang & Zhaoyang Tang & Huixia Pan & Xiaoping Li & Wei Wei & Jie Yang & Xu, 2022. "Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    7. Matthew T. Campbell & Surena F. Matin & Alda L. Tam & Rahul A. Sheth & Kamran Ahrar & Rebecca S. Tidwell & Priya Rao & Jose A. Karam & Christopher G. Wood & Nizar M. Tannir & Eric Jonasch & Jianjun Ga, 2021. "Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    8. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    9. Yu-Ting Yen & May Chien & Pei-Yi Wu & Chi-Chang Ho & Chun-Te Ho & Kevin Chih-Yang Huang & Shu-Fen Chiang & K. S. Clifford Chao & William Tzu-Liang Chen & Shih-Chieh Hung, 2021. "Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    10. Su Yin Lim & Elena Shklovskaya & Jenny H. Lee & Bernadette Pedersen & Ashleigh Stewart & Zizhen Ming & Mal Irvine & Brindha Shivalingam & Robyn P. M. Saw & Alexander M. Menzies & Matteo S. Carlino & R, 2023. "The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    11. Jodi M. Carter & Saranya Chumsri & Douglas A. Hinerfeld & Yaohua Ma & Xue Wang & David Zahrieh & David W. Hillman & Kathleen S. Tenner & Jennifer M. Kachergus & Heather Ann Brauer & Sarah E. Warren & , 2023. "Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    12. Fengqiao Li & Xue-Qing Zhang & William Ho & Maoping Tang & Zhongyu Li & Lei Bu & Xiaoyang Xu, 2023. "mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    13. Xinyu Bai & Grace H. Attrill & Tuba N. Gide & Peter M. Ferguson & Kazi J. Nahar & Ping Shang & Ismael A. Vergara & Umaimainthan Palendira & Ines Pires Silva & Matteo S. Carlino & Alexander M. Menzies , 2024. "Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    14. Michiel S. Heijden & Thomas Powles & Daniel Petrylak & Ronald Wit & Andrea Necchi & Cora N. Sternberg & Nobuaki Matsubara & Hiroyuki Nishiyama & Daniel Castellano & Syed A. Hussain & Aristotelis Bamia, 2022. "Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    15. Yingying Shen & Chaojie Lu & Zhengbo Song & Chenxiao Qiao & Jiaoli Wang & Jinbiao Chen & Chengyan Zhang & Xianchang Zeng & Zeyu Ma & Tao Chen & Xu Li & Aifu Lin & Jufeng Guo & Jianli Wang & Zhijian Ca, 2022. "Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    16. Arta M. Monjazeb & Megan E. Daly & Guillaume Luxardi & Emanual Maverakis & Alexander A. Merleev & Alina I. Marusina & Alexander Borowsky & Amin Mirhadi & Stephen L. Shiao & Laurel Beckett & Shuai Chen, 2023. "Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    17. Isaac Dean & Colin Y. C. Lee & Zewen K. Tuong & Zhi Li & Christopher A. Tibbitt & Claire Willis & Fabrina Gaspal & Bethany C. Kennedy & Veronika Matei-Rascu & Rémi Fiancette & Caroline Nordenvall & Ul, 2024. "Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    18. Lei Guan & Bin Wu & Ting Li & Lynn A. Beer & Gaurav Sharma & Mingyue Li & Chin Nien Lee & Shujing Liu & Changsong Yang & Lili Huang & Dennie T. Frederick & Genevieve M. Boland & Guangcan Shao & Tatyan, 2022. "HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    19. Yi Zhang & Mingjie Wang & Ling Ye & Shengqi Shen & Yuxi Zhang & Xiaoyu Qian & Tong Zhang & Mengqiu Yuan & Zijian Ye & Jin Cai & Xiang Meng & Shiqiao Qiu & Shengzhi Liu & Rui Liu & Weidong Jia & Xianzh, 2024. "HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    20. Rachael M. Zemek & Wee Loong Chin & Vanessa S. Fear & Ben Wylie & Thomas H. Casey & Cath Forbes & Caitlin M. Tilsed & Louis Boon & Belinda B. Guo & Anthony Bosco & Alistair R. R. Forrest & Michael J. , 2022. "Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:14:y:2017:i:1:p:68-:d:87618. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.